March 31, 2016
(Medscape) – The U.S. Food and Drug Administration said it would allow the use of an experimental test to screen donated blood for the Zika virus. The test, manufactured by Roche Holding AG, may be used for screening donated blood in areas with active mosquito-borne transmission of Zika virus, the FDA said. The regulator recommended last month that blood should no longer be collected from regions in the United States where the Zika virus is circulating.
The views, opinions and positions expressed by these authors and blogs are theirs and do not necessarily represent that of the Bioethics Research Library and Kennedy Institute of Ethics or Georgetown University.